| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
|
Mol Cancer Ther
|
2006
|
2.40
|
|
2
|
Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival.
|
Cancer Res
|
2008
|
2.20
|
|
3
|
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.
|
J Natl Cancer Inst
|
2007
|
2.03
|
|
4
|
The liposomal formulation of doxorubicin.
|
Methods Enzymol
|
2005
|
1.62
|
|
5
|
Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding.
|
Biochim Biophys Acta
|
2007
|
1.56
|
|
6
|
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.
|
Cancer Biol Ther
|
2011
|
1.47
|
|
7
|
Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.
|
Cancer Biol Ther
|
2004
|
1.39
|
|
8
|
A low carbohydrate, high protein diet slows tumor growth and prevents cancer initiation.
|
Cancer Res
|
2011
|
1.33
|
|
9
|
Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.
|
Cancer Res
|
2006
|
1.31
|
|
10
|
In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery.
|
Magn Reson Med
|
2004
|
1.20
|
|
11
|
Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.
|
Oncogene
|
2005
|
1.14
|
|
12
|
Chemodosimetry of in vivo tumor liposomal drug concentration using MRI.
|
Magn Reson Med
|
2006
|
1.08
|
|
13
|
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
|
Clin Cancer Res
|
2004
|
1.05
|
|
14
|
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.
|
PLoS One
|
2013
|
1.04
|
|
15
|
The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo.
|
J Pharm Sci
|
2010
|
1.02
|
|
16
|
Formation of transition metal-doxorubicin complexes inside liposomes.
|
Biochim Biophys Acta
|
2002
|
1.00
|
|
17
|
Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs.
|
Mol Cancer Ther
|
2007
|
1.00
|
|
18
|
Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin.
|
Clin Cancer Res
|
2008
|
0.99
|
|
19
|
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
|
Biochim Biophys Acta
|
2006
|
0.99
|
|
20
|
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.
|
Mol Cancer Ther
|
2006
|
0.99
|
|
21
|
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).
|
Mol Cancer Ther
|
2008
|
0.98
|
|
22
|
pH gradient loading of anthracyclines into cholesterol-free liposomes: enhancing drug loading rates through use of ethanol.
|
Biochim Biophys Acta
|
2004
|
0.95
|
|
23
|
Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids.
|
Biochim Biophys Acta
|
2002
|
0.92
|
|
24
|
In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine.
|
Eur J Pharm Biopharm
|
2006
|
0.91
|
|
25
|
Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes.
|
Vaccine
|
2003
|
0.91
|
|
26
|
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
|
Clin Cancer Res
|
2008
|
0.90
|
|
27
|
Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids.
|
J Pharmacol Exp Ther
|
2002
|
0.90
|
|
28
|
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
|
BMC Cancer
|
2011
|
0.90
|
|
29
|
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
|
Mol Cancer Res
|
2004
|
0.89
|
|
30
|
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo.
|
PLoS One
|
2013
|
0.88
|
|
31
|
Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
|
J Control Release
|
2010
|
0.87
|
|
32
|
Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
|
Clin Cancer Res
|
2004
|
0.87
|
|
33
|
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
|
Breast Cancer Res Treat
|
2007
|
0.87
|
|
34
|
An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
|
J Control Release
|
2004
|
0.87
|
|
35
|
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
|
Cancer Chemother Pharmacol
|
2009
|
0.87
|
|
36
|
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
|
J Control Release
|
2010
|
0.87
|
|
37
|
Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese.
|
J Control Release
|
2005
|
0.87
|
|
38
|
Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes.
|
Int J Pharm
|
2007
|
0.85
|
|
39
|
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
|
PLoS One
|
2013
|
0.85
|
|
40
|
Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity.
|
Nanomedicine (Lond)
|
2011
|
0.85
|
|
41
|
Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.
|
Biochim Biophys Acta
|
2002
|
0.85
|
|
42
|
Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.
|
Clin Cancer Res
|
2013
|
0.84
|
|
43
|
In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.
|
Clin Cancer Res
|
2004
|
0.84
|
|
44
|
Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
|
Prostate
|
2010
|
0.84
|
|
45
|
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.
|
PLoS One
|
2013
|
0.84
|
|
46
|
Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.
|
J Control Release
|
2005
|
0.83
|
|
47
|
Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.
|
J Pharm Sci
|
2010
|
0.82
|
|
48
|
Preparation, characterization, and biological analysis of liposomal formulations of vincristine.
|
Methods Enzymol
|
2005
|
0.82
|
|
49
|
Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
|
Clin Cancer Res
|
2004
|
0.81
|
|
50
|
siRNA-mediated integrin-linked kinase suppression: nonspecific effects of siRNA/cationic liposome complexes trigger changes in the expression of phosphorylated-AKT and mTOR independently of ILK silencing.
|
Oligonucleotides
|
2009
|
0.81
|
|
51
|
Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy.
|
Eur J Drug Metab Pharmacokinet
|
2002
|
0.81
|
|
52
|
Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis.
|
Biochim Biophys Acta
|
2003
|
0.81
|
|
53
|
A novel oral dosage formulation of the ginsenoside aglycone protopanaxadiol exhibits therapeutic activity against a hormone-insensitive model of prostate cancer.
|
Anticancer Drugs
|
2012
|
0.80
|
|
54
|
Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems.
|
Curr Gene Ther
|
2006
|
0.80
|
|
55
|
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
|
BMC Cancer
|
2011
|
0.79
|
|
56
|
Copper-topotecan complexation mediates drug accumulation into liposomes.
|
J Control Release
|
2006
|
0.79
|
|
57
|
Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids.
|
Biochim Biophys Acta
|
2002
|
0.79
|
|
58
|
The formulation of lipid-based nanotechnologies for the delivery of fixed dose anticancer drug combinations.
|
Curr Drug Deliv
|
2005
|
0.78
|
|
59
|
Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
|
Nanomedicine (Lond)
|
2011
|
0.78
|
|
60
|
Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes.
|
Vaccine
|
2004
|
0.78
|
|
61
|
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
|
Invest New Drugs
|
2014
|
0.78
|
|
62
|
Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
|
Nucleic Acids Res
|
2002
|
0.78
|
|
63
|
Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.
|
Nanomedicine (Lond)
|
2014
|
0.78
|
|
64
|
Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells.
|
Int J Pharm
|
2002
|
0.77
|
|
65
|
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
|
Invest New Drugs
|
2012
|
0.77
|
|
66
|
Trastuzumab and liposomal Doxorubicin in the treatment of mcf-7 xenograft tumor-bearing mice: combination does not affect drug serum levels.
|
Pharm Res
|
2005
|
0.77
|
|
67
|
Liposomal drug delivery: recent patents and emerging opportunities.
|
Recent Pat Drug Deliv Formul
|
2007
|
0.75
|
|
68
|
Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy.
|
Nanomedicine (Lond)
|
2006
|
0.75
|
|
69
|
Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.
|
J Exp Ther Oncol
|
2003
|
0.75
|
|
70
|
A parenteral econazole formulation using a novel micelle-to-liposome transfer method: in vitro characterization and tumor growth delay in a breast cancer xenograft model.
|
Pharm Res
|
2006
|
0.75
|